Ann: Imugene appoints experienced life sciences CFO Mike Tonroe, page-41

You could be right. Given biotech's sensitive (secretive) nature, especially within the oncology space, we shareholders have to speculate. It's healthy and useful.

If it's much of the same, then why hire someone at all (especially considering in-house CFO costs). Between R&D and payroll, IMU accounting arguably has been quite similar the past few years. The only major difference is increased costs for clinical trials.

I'll put my hat in the ring and say this has been done in anticipation of revenues to be forthcoming within the next 6-9 months. On the balance of probability, revenues are mainly in USD. This could lead to a possible dual listing, we already meet one of the prerequisites with IMU on the OTC market. It also shows boards' previous behaviour of seeing value in US investment. Would also help with the currency/exchange issue, as a decent proportion of our outgoings would be in USD where clinical trials are taking place.

Let's wait and see.

IMO DYOR